AAAAAA
Results:
1-21
|
Results: 21
Authors:
Kvist, EE
Al-Shurbaji, A
Dahl, ML
Nordin, C
Alvan, G
Stahle, L
Citation: Ee. Kvist et al., Quantitative pharmacogenetics of nortriptyline - A novel approach, CLIN PHARMA, 40(11), 2001, pp. 869-877
Authors:
Scordo, MG
Aklillu, E
Yasar, U
Dahl, ML
Spina, E
Ingelman-Sundberg, M
Citation: Mg. Scordo et al., Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population, BR J CL PH, 52(4), 2001, pp. 447-450
Authors:
Roh, HK
Chung, JY
Oh, DY
Park, CS
Svensson, JO
Dahl, ML
Bertilsson, L
Citation: Hk. Roh et al., Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients, BR J CL PH, 52(3), 2001, pp. 265-271
Authors:
Carlsson, B
Olsson, G
Reis, M
Walinder, J
Nordin, C
Lundmark, J
Scordo, MG
Dahl, ML
Bengtsson, F
Ahlner, J
Citation: B. Carlsson et al., Enantioselective analysis of citalopram and metabolites in adolescents, THER DRUG M, 23(6), 2001, pp. 658-664
Authors:
Yasar, U
Tybring, G
Hidestrand, M
Oscarson, M
Ingelman-Sundberg, M
Dahl, ML
Eliasson, E
Citation: U. Yasar et al., Role of CYP2C9 polymorphism in losartan oxidation, DRUG META D, 29(7), 2001, pp. 1051-1056
Authors:
Alvan, G
Bertilsson, L
Dahl, ML
Ingelman-Sundberg, M
Sjoqvist, F
Citation: G. Alvan et al., Moving toward genetic profiling in patient care: The scope and rationale of pharmacogenetic/ecogenetic investigation, DRUG META D, 29(4), 2001, pp. 580-585
Authors:
Benitez, J
Dahl, ML
Spina, E
Carrillo, JA
Citation: J. Benitez et al., Genetic and environmental factors causing variability in psychotropic drugresponse, INTERINDIVIDUAL VARIABILITY IN HUMAN DRUG METABOLISM, 2001, pp. 85-128
Authors:
Kirchheiner, J
Brosen, K
Dahl, ML
Gram, LF
Kasper, S
Roots, I
Sjoqvist, F
Spina, E
Brockmoller, J
Citation: J. Kirchheiner et al., CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages, ACT PSYC SC, 104(3), 2001, pp. 173-192
Authors:
Llerena, A
Kiivet, RA
Dahl, ML
Vega, JS
Rootslane, L
Wettermark, B
Citation: A. Llerena et al., Psychotropic drug use in non-psychiatric departments of three European university hospitals, NORD J PSY, 54(1), 2000, pp. 61-65
Authors:
Dalen, P
Dahl, ML
Andersson, K
Bertilsson, L
Citation: P. Dalen et al., Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes, BR J CL PH, 49(2), 2000, pp. 180-184
Authors:
Carrillo, JA
Christensen, M
Ramos, SI
Alm, C
Dahl, ML
Benitez, J
Bertilsson, L
Citation: Ja. Carrillo et al., Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine, THER DRUG M, 22(4), 2000, pp. 409-417
Authors:
Dahl, ML
Sjoqvist, F
Citation: Ml. Dahl et F. Sjoqvist, Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics, THER DRUG M, 22(1), 2000, pp. 114-117
Authors:
Scordo, MG
Spina, E
Romeo, P
Dahl, ML
Bertilsson, L
Johansson, I
Sjoqvist, F
Citation: Mg. Scordo et al., CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients, EUR J CL PH, 56(9-10), 2000, pp. 679-683
Authors:
Sagar, M
Tybring, G
Dahl, ML
Bertilsson, L
Seensalu, R
Citation: M. Sagar et al., Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism, GASTROENTY, 119(3), 2000, pp. 670-676
Authors:
Scordo, MG
Spina, E
Facciola, G
Avenoso, A
Johansson, I
Dahl, ML
Citation: Mg. Scordo et al., Cytochrome P450 2D6 genotype and steady state plasma levels of risperidoneand 9-hydroxyrisperidone, PSYCHOPHAR, 147(3), 1999, pp. 300-305
Authors:
Dalen, P
Dahl, ML
Eichelbaum, M
Bertilsson, L
Wilkinson, GR
Citation: P. Dalen et al., Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes, PHARMACOGEN, 9(6), 1999, pp. 697-706
Authors:
Wennerholm, A
Johansson, I
Massele, AY
Jande, M
Alm, C
Aden-Abdi, Y
Dahl, ML
Ingelman-Sundberg, M
Bertilsson, L
Gustafsson, LL
Citation: A. Wennerholm et al., Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype, PHARMACOGEN, 9(6), 1999, pp. 707-714
Authors:
Bernal, ML
Sinues, B
Johansson, I
McLellan, RA
Wennerholm, A
Dahl, ML
Ingelman-Sundberg, M
Bertilsson, L
Citation: Ml. Bernal et al., Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine, PHARMACOGEN, 9(5), 1999, pp. 657-660
Authors:
Yasar, U
Eliasson, E
Dahl, ML
Johansson, I
Ingelman-Sundberg, M
Sjoqvist, F
Citation: U. Yasar et al., Validation of methods for CYP2C9 genotyping: Frequencies of mutant allelesin a Swedish population (vol 254, pg 628, 1999), BIOC BIOP R, 258(1), 1999, pp. 227-227
Authors:
Yasar, U
Eliasson, E
Dahl, ML
Johansson, I
Ingelman-Sundberg, M
Sjoqvist, F
Citation: U. Yasar et al., Validation of methods for CYP2C9 genotyping: Frequencies of mutant allelesin a Swedish population, BIOC BIOP R, 254(3), 1999, pp. 628-631
Authors:
Yamada, H
Dahl, ML
Viitanen, M
Winblad, B
Sjoqvist, F
Lannfelt, L
Citation: H. Yamada et al., No association between familial Alzheimer disease and cytochrome P450 polymorphisms, ALZ DIS A D, 12(3), 1998, pp. 204-207
Risultati:
1-21
|